This acquisition will allow barda to invest project bioshield funds for late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat…
Active Definitive Contract Awarded Last action
- Contract number
- 75A50122C00082
- Awardee
-
Aktivax, Inc. UEI T1XHPCDJ4NT6
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $45,323,792
Award facts
- Opportunity
-
- 2 PAM Autoinjectors Pre-Solicitation · 75A50122R00022 · Posted Jun 15, 2022
- Contract value 21% obligated
-
- $45,323,792.00 Current, with exercised options
- $220,246,768.00 Potential, with all options
- Completion date 24% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Broomfield, CO 80021, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $45,323,792 |
About this award
The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $220,246,768 Definitive Contract to Aktivax, Inc. to support late-stage clinical development, regulatory approval, and procurement of 2-PAM autoinjectors as a drug-device combination product to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations. This acquisition, which is not set-aside, will allow ASPR's Biomedical Advanced Research and Development Authority (BARDA) to invest Project BioShield funds for this purpose. Upon FDA approval by the end of 2024, Aktivax must be capable of manufacturing and delivering 2 million 600 mg 2-PAM autoinjectors to the Strategic National Stockpile by September 2029.
Description
This acquisition will allow barda to invest project bioshield funds for late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agent
Quick answers
Who was awarded contract 75A50122C00082?
75A50122C00082 was awarded to Aktivax, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2022.
How much is contract 75A50122C00082 worth?
The government has obligated $45,323,792 on 75A50122C00082. Its potential value, with all options, is $220,246,768.
Was contract 75A50122C00082 competed?
The extent of competition for 75A50122C00082 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award